Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma

About 50% of melanomas harbour a BRAF mutation. Of these 50%, 10% have a V600K mutation. Although it is the second most common driver mutation after V600E, no specific studies have been conducted to identify a clinical and therapeutic gold standard for this patient subgroup. We analysed articles, in...

Full description

Bibliographic Details
Main Authors: Alessandro Nepote, Gianluca Avallone, Simone Ribero, Francesco Cavallo, Gabriele Roccuzzo, Luca Mastorino, Claudio Conforti, Luca Paruzzo, Stefano Poletto, Fabrizio Carnevale Schianca, Pietro Quaglino, Massimo Aglietta
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Journal of Clinical Medicine
Subjects:
cutaneous melanoma
BRAF mutation
BRAF V600K
target therapy
immunotherapy
Online Access:https://www.mdpi.com/2077-0383/11/3/828

Internet

https://www.mdpi.com/2077-0383/11/3/828

Similar Items